Table 1.
Baseline Demographic and Disease Characteristics by Bilirubin Level at Diagnosis of VOD/SOS
| Bilirubin Level at Diagnosis of VOD/SOS* | |||
|---|---|---|---|
| Characteristic | All VOD/SOS Post-HCT (N = 803) | <2 mg/dL (n = 181) | ≥2 mg/dL (n = 613) |
| Age at HCT, yr, median (range) | 12 (<1-77) | 4 (<1-71) | 15 (<1-77) |
| Age class at HCT, n (%) | |||
| ≤16 yr | 466 (58) | 132 (73) | 328 (54) |
| >16 yr | 337 (42) | 49 (27) | 285 (47) |
| Diagnostic criteria, n (%) | |||
| Modified Seattle criteria† | 331 (41) | 165 (91) | 158 (26) |
| Baltimore criteria | 449 (56) | 0 | 449 (73) |
| Biopsy† | 23 (3) | 16 (9) | 6 (1) |
| Primary disease, n (%) | |||
| Acute myelogenous leukemia | 203 (25) | 53 (29) | 147 (24) |
| Acute lymphoblastic leukemia | 152 (19) | 17 (9) | 134 (22) |
| Myelodysplastic syndrome | 40 (5) | 5 (3) | 35 (6) |
| Neuroblastoma | 101 (13) | 51 (28) | 48 (8) |
| Graft-versus-host disease prophylaxis, n (%) | |||
| None | 160 (20) | 64 (35) | 93 (15) |
| Tacrolimus | 396 (49) | 93 (51) | 297 (49) |
| Methotrexate | 263 (33) | 49 (27) | 209 (34) |
| Cyclosporine | 209 (26) | 14 (8) | 195 (32) |
| Sirolimus | 61 (8) | 17 (9) | 44 (7) |
| Other (not specified) | 294 (37) | 43 (24) | 250 (41) |
| Type of HCT, n (%) | |||
| Allogenous | 660 (82) | 122 (67) | 531 (87) |
| Autogenous | 141 (18) | 59 (33) | 80 (13) |
| Unknown | 2 (<1) | 0 | 2 (<1) |
| MOD present, n (%) | 352 (44) | 54 (30) | 295 (48) |
*
Of the 803 post-HCT patients in the T-IND, 9 had missing data on bilirubin level at diagnosis.
†
Bilirubin data were missing for 8 patients diagnosed using the Seattle criteria and for 1 patient diagnosed by biopsy.